A preliminary study of immunotherapy with a monomethoxy polyethylene glycol modified honey bee venom preparation.
Monomethoxy polyethylene glycol (mPEG) modified honey bee venom (HBV) immunotherapy (IT) has been studied in 14 patients allergic to honey bee venom. Doses could be increased more rapidly and higher doses were reached compared to regular venom immunotherapy. No general side effects were seen, although large local swellings were found somewhat more often than with regular HBV. Most patients could easily be switched from the modified to the unmodified venom. Eight patients experienced and tolerated field stings. Skin testing showed a decreased allergenicity of the mPEG-HBV. The mean HBV-specific IgE level was below pre-treatment level already after only 6 weeks of IT. The HBV-specific IgG response was very good.
S
S
Ohman
J
J
Björkander
S
S
Dreborg
A
A
Lanner
H J
HJ
Malling
B
B
Weeke
D000328:Adult; D001514:Bee Venoms / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006967:Hypersensitivity; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012882:Skin Tests
D001514:Bee Venoms; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol